RBC Capital Maintains Outperform on Mirum Pharmaceuticals, Raises Price Target to $155

Benzinga · 2d ago
RBC Capital analyst Lisa Walter maintains Mirum Pharmaceuticals (NASDAQ:MIRM) with a Outperform and raises the price target from $135 to $155.